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A good correlation was observed between enhanced lung cancer risk and restriction fragment length polymorphisms (RFLPs) of the P450IAl gene 
with the restriction enzyme. MspI. Genotype frequencies of 0.49 for the predominant homozygote, 0.40 for the heterozygote, and 0.11 for the homo- 
zygous rare allele were observed in a healthy population. Among lung cancer patients, the frequency of homozygous rare allele of P450IAl gene 
was found to be about 3-fold higher than that among healthy population, and this difference was statistically significant. This is the first report 
to identify the genetically high risk individuals to lung cancer at the gene level. 
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1. INTRODUCTION 
Microsomal mixed-function oxidations are essential 
in the metabolism of drugs, steroids and chemical car- 
cinogens [ 1,2]. Genetic variation among individuals in 
metabolism have been reported [3,4], and variations in 
the oxidative activation of chemical carcinogens might 
well explain differences in susceptibility of individuals 
to chemical carcinogens [2]. The metabolism of 
chemical carcinogens involves a variety of isozymes of 
cytochrome P450, and differences in their genotypes or 
phenotypes may be a main factor responsible for dif- 
ferences among individuals in susceptibility to car- 
cinogens. 
phisms associated with genetically determined dif- 
ferences among individuals in their susceptibility to 
lung cancer. 
2. EXPERIMENTAL 
Lung cancer is one of the most common cancers in 
all countries, and squamous cell carcinoma is known to 
be caused by cigarette smoking. Initiation of the car- 
cinoma requires metabolic activition of the procar- 
cinogens such as benzo(a)pyrene to the ultimate form 
by cytochrome P450IAl (so-called P-450~ or Pi-450) 
[5]. Accumulated evidence [6,7] suggests that increased 
risk of smoking-induced bronchogenic carcinoma is 
associated with high activity of aryl-hydrocarbon 
hydroxylase (AHH), an inducibility phenotype of 
P450IAl. 
Blood samples (7-15 ml) were obtained from individuals, and 
DNA was isolated from peripheral lymphocytes. Human lymphocyte 
DNA (8 cg) was digested completely with restriction endonuclease 
MspI (Takara, 60 units) for 3 h at 37°C and the products were sub- 
jected to electrophoresis n 0.8% agarose for Southern blot analysis 
191. The DNA fragments were transferred to a nitrocellulose mem- 
brane (Schleicher and Schiill), incubated with nick-translated DNA 
probes labeled with ‘*P-dCTP (Amersham). 
The DNA fragment including MspI site at 3047 was amplified from 
the individual (lane 1 in Fig. 2a) by PCR method [lo]. Used were the 
primers of 21 bases from 2901 of the coding and 3197 of the reverse 
complement sequence of P450IAl gene [ll]. 
3. RESULTS AND DISCUSSION 
Restriction fragment length polymorphisms (RFLPs) 
of human P450IAl gene have been detected [8], 
although no association with cancer incidence has been 
reported. In this paper, we report that A4spI polymor- 
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When lymphocyte DNAs were digested with MspI 
and hybridized with the XbaI-EcoRI fragment (probe 1 
in Fig. la), clear RFLPs of the P450IAl gene were 
observed among individuals. Fig. 2a shows represen- 
tative results on DNA polymorphisms observed in 
unrelated individuals by Southern blot analysis. The 
RFLPs detected with A&p1 can be classified into 3 
types: type A is characterized by 2.7, 2.3, and 0.8 kb 
fragments (lanes 3,4, 5 and 8in Fig. 2a), type B by 2.7, 
2.3, 1.9 and 0.8 kb (lanes 6, 7, 9 and lo), and type C 
by 2.7, 1.9 and 0.8 kb (lane 11). The lengths of these 
bands agreed well with those determined by sequence 
analysis (Fig. lb) [l I]. Our results by Southern blot 
(Fig. 2a) and sequence (Fig. lb) analyses showed that 
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Fig. 1. Structural organization and restriction cleavage sites for Mspi 
of the P450IAl gene. The restriction map and organization of the 
P450IAl gene cloned into hhP-450mc-1 [ll] are shown in (a). The 
exons are shown by closed boxes and restriction sites are marked by 
X for X&u1 and E for EcoRI. Sites of MS@ were determined from 
sequence analysis [l l] and shown in (b) by vertical ines. The two sites 
indicated by A and +r are origins of pol~o~hisms as described in 
the text. The probes used are shown by 1 and 2 in (a). The fragment 
lengths corresponding to the observed bands are shown in (b). 
the 3 polymorphisms originated from presence or 
absence of one A&p1 site (A in Fig. 1 b) at the 3 ’ -end. 
We then carried out genomic blot analysis using the 
EcoRI-EcoRI fragment (probe 2 in Fig. la) and found 
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Fig. 2. DNA polymorphisms of the P450IAl gene by MspI. (a) Probe 
1 (X&I to EcoRI in Fig. la) was used for unrelated individuals. 
XDNA digested with Hind111 was used as a size marker. (b) Probe 2 
(EcoRI to EcoRI in Fig. la) was used, Lanes l-4 were obtained from 
the same DNA as lanes 11, 1, 3 and 9, respectively, in (a). (c) 
Polymorphisms of related individuals examined with probe 1. Lanes 
1, 2 and 3 show paternal, maternal DNA and that of their child, 
respectively. 
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3 types of MspI polymorphisms (Fig. 2b). We also ob- 
tained the segregation profile of polymorphic MspI 
fragments by family pedigree analysis (Fig. 2~). Accor- 
dingly, we concluded that the 3 polymorphisms con- 
sisted of two homozygous (types A and C) and one 
heterozygous tates (type B) at a single locus. 
In a few subjects, we observed an additional band of 
I.0 kb (lanes 1 and 2 in Fig. 2a). The gene sequence 
ill] suggested that this band could be produced by a 
point mutation or methylation of the h&p1 site in the 
2nd exon at 3047 (* in Fig. lb) from the transcription- 
initiation site [ 111. We concluded, however, that it was 
not ascribable to a point mutation of the M&I site, but 
to specific methylation of the site, because agarose gel 
electrophoresis of the DNA ampli~ed by PCR with 
MspI digestion showed a complete digestion pattern 
(Fig. 3). 
We then determined the frequency of each type of 
MspI polymorphism in the general population. We 
isolated lymphocyte DNA from a cohort of 1500 per- 
sons of over 40 years old and analyzed the DNA 
polymorphisms of 104 randomly selected subjects as 
healthy controls (Table I). Types A (ml/ml), B 
(ml/m2), and C (m2/m2) were found respectively in 
5 l,, 42 and 11 of these healthy controls. This result gave 
a good fit to the Hardy-Weinberg equilibrium with a 
gene frequency of 0.69 for ml and 0.31 for m2. 
In Table I, the frequencies of genotypes among lung 
cancer patients were different from those among 
healthy controls with statistical significance of P < 0.05 
(x2 = 6.182 with d.f. = 2). In addition, the comparison 
of genotypes A+ B or A with C in frequencies also 
showed signi~cant difference with P < 0.05, allowing 
us to estimate the risk elevation (odds ratio) of C type 
to be 2.6 or 3.1 compared with A + B or A types. 
Among the histological types, the squamous cell car- 
cinoma gave remarkable deviation of frequencies from 
Fig. 3. MspI digestion of amplified DNA indicating specific 
methylation of the MspI site at 3047 of the P459AIl gene. Lanes 3 
and 2 were digested with or without Mspf;“and lane 1 is a size marker 
of W-40 DNA digested with HindfIt. 
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Table 1 
Distribution of the 3 types of P45OIAl gene among lung cancer 
patients and healthy controls 
Population P450IAl genotye Total 
A(ml/ml)B(ml/m2)C(m2/m2) 
Healthy controls (H) 
Lung cancer (L) 
Squamous cell 
carcinoma (S) 
Small cell carcinoma 
Large cell carcinoma 
Adenocarcinoma 
Odds ratio 
Between H and L 
Between H and S 
51(49.0) 42(40.4) 1 l(10.6) 104(100%) 
24(35.3) 28(41.2) 16(23.5) 68(100) 
7(30.4) 9(39.1) 7(30.4) 23(100) 
g(44.5) 6(33.3) 4(22.2) 18(100) 
l(16.7) 4(66.6) l(16.7) 6(lOO) 
g(38.1) 9(42.9) 4(19.0) 21(100) 
1.0 1.417 3.091 
1.0 2.601 
1.0 1.561 4.636 
1.0 3.699 
Risk of C type relative to A or A + B type is also shown as odds ratio 
the healthy controls h2 = 6.675 with d.f. = 2). The risk 
of C type was calculated to be about 5-fold for this cell 
type of lung cancer comparing with A type. We con- 
clude that the individuals with the homozygote rare 
allele of MspI polymorphisms for the P450IAl gene are 
at 3--5fold higher risk of lung cancer, especially 
squamous cell carcinoma, than those with other 
genotypes. This risk elevation of C type was specifically 
observed for lung cancer because the frequencies of C 
type among other two cancers were identical to those of 
healthy controls (5 out of 39 stomach cancer patients 
and 3 out of 31 breast cancer patients). 
The frequency of 3 genotypes for P450IAl among 
healthy controls showed an excellent agreement with 
the frequencies of tri-modal AHH inducibility observed 
in general population [12,13]. Moreover, the propor- 
tion of patients with the homozygote rare allele (type C) 
among those with squamous cell carcinoma was the 
same as that of patients with the high AHH phenotype 
among those with bronchogenic arcinoma [6]. The dif- 
ference of P450IAl genotypes in risk of lung cancer 
may be explained by the tri-modal AHH inducibility. 
To examine this, we are now comparing the structures 
and expressions of the genotypes of P450IAl. 
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